BNR stock forecast, quote, news & analysis
Burning Rock Biotech Ltd is a cancer diagnostics company... Show more
Why Burning Rock Biotech (BNR) Stock Is Down -37% in the Last 30 Days
Key Takeaways
- Burning Rock Biotech (BNR) shares fell roughly 37% over the past 30 days, from about $16.25 to around $10.19, after a sharp rally briefly pushed the stock above $18 in late September.
- The decline reflects profit-taking and a valuation reset following a September surge tied to regulatory milestones, personalized MRD kit designations, and a global licensing partnership with Myriad Genetics (MYGN).
- Over the broader three-month window, BNR remains approximately 15% higher, underscoring the stock's high volatility rather than a single-direction trend.
- Second-quarter 2026 results, reported on September 10, showed total revenue of RMB134.7 million (US$19.9 million), down 9.3% year over year, alongside a widened net loss of RMB18.4 million.
- The company continues to advance a pipeline of next-generation sequencing (NGS) diagnostics, including liquid biopsy and personalized minimal residual disease (MRD) tests under priority review in China.
- Get more insight into Burning Rock's Price Targets, Earnings, and Forecast on Tickeron's dedicated pages.
- Explore Trending AI Robots to discover top-performing AI trading bots that monitor BNR and thousands of other tickers.
Burning Rock Biotech (BNR) Company Overview and Market Position
Burning Rock Biotech Limited is a China-based precision oncology company that applies next-generation sequencing (NGS) technology to cancer diagnostics. Founded in 2014 and headquartered in Guangzhou, the company operates across three segments: central laboratory testing, in-hospital testing, and pharmaceutical research and development services. Its portfolio includes tissue- and liquid-biopsy-based therapy selection tests such as OncoScreen Plus and OncoCompass Plus, along with minimal residual disease (MRD) monitoring and companion diagnostic development for global drugmakers.
The company has established itself as a leading NGS-based diagnostics provider in China, supported by CAP-accredited and CLIA-certified laboratories and collaborations with more than 150 pharmaceutical companies. Investors follow BNR for its regulatory pipeline, expanding in-hospital testing footprint, and progress toward profitability, even as the business remains unprofitable and exposed to the volatile Chinese healthcare market.
Burning Rock Biotech (BNR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BNR has fallen approximately 37%, declining from a closing price of about $16.25 in early October to roughly $10.19. The pullback marked a sharp reversal after the stock had rallied from roughly $9.25 at the start of September to a late-September closing high near $18.94, meaning the shares roughly doubled before giving back a substantial portion of those gains.
Over the last quarter, the picture is different. From an early-August level near $8.84, BNR is still up approximately 15%, reflecting the steep September climb that preceded October's correction. The gap between the 30-day decline and the positive quarterly reading highlights a highly volatile, momentum-driven trading pattern rather than a stable directional trend. BNR's 52-week range of roughly $6.79 to $41.72 further illustrates this volatility.
What Drove BNR Stock Price in the Last 30 Days
The recent 30-day decline was primarily a correction of an unusually rapid rally rather than a response to a single negative corporate event. After more than doubling in September, the stock became susceptible to profit-taking, particularly as independent valuation analyses flagged the shares as trading well above estimated intrinsic value at their September peak. The October pullback brought the stock back toward its pre-rally levels, with several sessions showing double-digit percentage declines on elevated volume.
The retreat occurred against a backdrop of mixed fundamentals. Second-quarter 2026 results showed a 9.3% year-over-year revenue decline to RMB134.7 million and a widened net loss of RMB18.4 million, even as in-hospital revenue rose 7.4% year over year and management emphasized a sequential recovery. Those results, combined with the stock's extended valuation, contributed to the corrective price action.
What Drove BNR Stock Performance Over the Last Quarter
The broader three-month trend was defined by a powerful September rally followed by an October correction. The rally was supported by a series of regulatory and partnership catalysts. In July 2026, the company announced a global technology licensing collaboration with Myriad Genetics to expand homologous recombination deficiency (HRD) testing worldwide. In August and September, Burning Rock's CanCatch Custom Kit and CanCatch Custom Kit (cPAS) entered China's Special Review Procedure for Innovative Medical Devices, and on September 24 a circulating tumor DNA multi-gene mutation detection kit entered the NMPA's priority review pathway.
These milestones drove substantial buying interest and elevated volume through late September. The subsequent pullback largely unwound the speculative portion of those gains, leaving the stock moderately higher over the full quarter as investors weighed the regulatory progress against still-negative earnings and valuation concerns.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's artificial-intelligence-driven trading bots. While Tickeron offers hundreds of AI bots that monitor thousands of tickers across multiple markets, only the top-performing and most relevant bots appear in this featured section. Each bot operates with its own strategy, timeframe, and performance metrics, allowing users to compare approaches that range from short-term momentum to longer-horizon trend following. For investors seeking a systematic, data-driven perspective on stocks like BNR, reviewing these bots can provide an additional lens alongside traditional fundamental and technical analysis.
BNR Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape BNR's outlook. Regulatory progress remains central, including potential approvals for its liquid biopsy and MRD kits currently under priority review, as well as the commercialization of its OncoScreen BCMatch breast cancer companion diagnostic. Investors should also monitor in-hospital testing adoption, pharmaceutical R&D services revenue, and whether the company sustains its recent operating-cost discipline and moves toward breakeven or positive cash flow.
Macroeconomic and sector risks include policy shifts affecting China's healthcare and diagnostics market, reimbursement changes, and broader sentiment toward China-listed equities. Competitive pressures in the NGS diagnostics space and foreign-exchange movements between the renminbi and U.S. dollar may also influence reported results. As always, these factors present both opportunities and risks rather than guarantees of any specific price outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BNR in upward trend: price may jump up because it broke its lower Bollinger Band on October 16, 2026
BNR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where BNR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on BNR as a result. In 70 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for BNR just turned positive on November 06, 2026. Looking at past instances where BNR's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Following a +6.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNR advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
BNR moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNR crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BNR entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.258) is normal, around the industry mean (67.298). P/E Ratio (-1.157) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.741) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. BNR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the investment of medical fields and specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology
Industry MedicalSpecialties